BioArctic AB announced today that the Japanese Patent Office (JPO) has allowed the company’s Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimers disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. BioArctic received a patent in Europe based on the same antibodies in January 2021.
- Read more about BioArctic receives patent in Japan for new antibodies targeting Alzheimers disease
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/bioarctic-receives-patent-in-japan-for-new-antibodies-targeting-alzheimers-disease
No comments:
Post a Comment